The Scott of Pot At It Again.. Cann Group aiming for over-the-counter CBD approval in late 2022

CANNANNEW REPORT

We presume the angle is getting liberal party members to give approval and buy stock at the same time so they can all get rich selling placebo CBD to all those idiots who refuse to get vaccinated for COVID. Here’s the mindless blurb Phase I clinical trial of the Satipharm CBD capsules in which results demonstrated the safety and high performance of the oral capsule technology, including the superior delivery profile of cannabidiol (CBD) compound to trial subjects. Phase II clinical trial of the Satipharm CBD capsules showed significantly reduced monthly seizure frequency in the treatment of children suffering from refractory, or treatment-resistant epilepsy when the Satipharm capsules were added to current medications. The treatment was generally well tolerated and the median reduction in seizures was 81.9% following 12 weeks of treatment. We’ll let Pondering Pot tell you what the angle is Cann Group (ASX: CAN) aiming for over-the-counter CBD approval in late 2022

Excerpt only …
READ MORE BELOW
Source : The Scott of Pot At It Again.. Cann Group aiming for over-the-counter CBD approval in late 2022

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.